Preclinical advances in antibodies against N-terminal Aβ4-x species for Alzheimer's disease and cerebral amyloid angiopathy

Abstract

Alzheimer's disease (AD) pathogenesis is characterized by the accumulation of amyloid beta (Aβ) deposits in the cerebral parenchyma and vasculature, a condition referred to as cerebral amyloid angiopathy (CAA). Besides the full-length form, Aβ deposits showed a highly heterogenous composition due to the action of different proteolytic enzymes. N-terminal Aβ peptides have shown higher aggregation propensity and toxicity compared to the other truncated forms, with species starting at residue phenylalanine 4 (Aβ4-x) being more neurotoxic than the others. Thus, Aβ4-x species have drawn attention in AD pathogenesis, potentially offering novel therapeutic targets to halt or reverse disease progression. Antibodies targeting specifically Aβ4-x species were designed with the aim of preventing their aggregation and promoting their clearance counterbalancing their neurotoxic effect. This work provides an update on monoclonal and polyclonal antibodies developed to specifically target Aβ4-x species in AD and CAA preclinical studies (in vitro and in vivo models).

Keywords

Alzheimer's disease (AD) / amyloid beta / cerebral amyloid angiopathy / immunotherapy / preclinical studies

References

[1] Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125.

[2] St George-Hyslop PH. Molecular genetics of Alzheimer's disease. Biol Psychiatry. 2000;47(3):183-199.

[3] Rodrigue KM, Kennedy KM, Park DC. Beta-amyloid deposition and the aging brain. Neuropsychol Rev. 2009;19(4):436-450.

[4] O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci. 2011;34: 185-204.

[5] Evin G, Barakat A. Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease. Degener Neurol Neuromusc Dis. 2014;4:1-19.

[6] Miller DL, Papayannopoulos IA, Styles J, et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Archives Biochem Biophys. 1993;301(1):41-52.

[7] Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in alzheimer disease and Down syndrome. Proc Natl Acad Sci. 1985;82(12):4245-4249.

[8] Prelli F, Castano E, Glenner GG, Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem. 1988;51(2):648-651.

[9] Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain. Neurosci Lett. 1996;215(3):173-176.

[10] Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem. 1992;267(24):17082-17086.

[11] Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. J Biol Chem. 1995;270(41):23895-23898.

[12] Jin Y, Du Q, Song M, et al. Amyloid-β-targeting immunotherapies for Alzheimer's disease. J Control Release. 2024;375:346-365.

[13] Rafii MS, Aisen PS. Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2025;21:490-498.

[14] Valiukas Z, Ephraim R, Tangalakis K, Davidson M, Apostolopoulos V, Feehan J. Immunotherapies for Alzheimer's disease-a review. Vaccines. 2022;10(9):1527.

[15] Kummer MP, Heneka MT. Truncated and modified amyloid-beta species. Alzheimer's Res Ther. 2014;6(3):28.

[16] Bayer TA. N-Truncated Aβ starting at position four-biochemical features, preclinical models, and potential as drug target in Alzheimer's disease. Front Aging Neurosci. 2021;13:710579.

[17] Bayer TA, Wirths O. Focusing the amyloid cascade hypothesis on N-truncated abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathol. 2014;127(6):787-801.

[18] Wirths O, Zampar S, Weggen S. N-Terminally truncated Aβ peptide variants in Alzheimer's disease. In: Wisniewski T, ed. Alzheimer's Disease. Codon Publications; 2019.

[19] Lewis H, Beher D, Cookson N, et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-β(42) peptide in vascular dementia. Neuropathol Appl Neurobiol. 2006;32(2):103-118.

[20] Portelius E, Lashley T, Westerlund A, et al. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry. Neurodegener Dis. 2015;15(1):50-57.

[21] Kasri A, Camporesi E, Gkanatsiou E, et al. Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer's disease with APPdup and Down syndrome. Acta Neuropathologica. 2024;148(1):8.

[22] Sergeant N, Bombois S, Ghestem A, et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem. 2003;85(6):1581-1591.

[23] Wildburger NC, Esparza TJ, LeDuc RD, et al. Diversity of amyloid-beta proteoforms in the Alzheimer's disease brain. Sci Rep. 2017;7(1):9520.

[24] Moore BD, Chakrabarty P, Levites Y, et al. Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. Alzheimer's Res Ther. 2012;4(3):18.

[25] Portelius E, Bogdanovic N, Gustavsson MK, et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 2010;120(2):185-193.

[26] Bouter Y, Dietrich K, Wittnam JL, et al. N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol. 2013;126(2):189-205.

[27] Parodi-Rullán R, Ghiso J, Cabrera E, Rostagno A, Fossati S. Alzheimer's amyloid β heterogeneous species differentially affect brain endothelial cell viability, blood-brain barrier integrity, and angiogenesis. Aging Cell. 2020;19(11):e13258.

[28] Rostagno A, Cabrera E, Lashley T, Ghiso J. N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer's pathophysiology. Transl Neurodegener. 2022;11(1):30.

[29] Rostagno A, Neubert TA, Ghiso J. Unveiling brain Aβ heterogeneity through targeted proteomic analysis. Methods Mol Biol. 2018;1779:23-43.

[30] Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG. Amyloid β protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun. 2000;276(2):422-427.

[31] Dammers C, Schwarten M, Buell AK, Willbold D. Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways. Chem Sci. 2017;8(7):4996-5004.

[32] Antonios G, Saiepour N, Bouter Y, et al. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathol Commun. 2013;1:56.

[33] Wirths O, Multhaup G, Bayer TA. A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide – the first step of a fatal cascade. J Neurochem. 2004;91(3):513-520.

[34] Casas C, Sergeant N, Itier JM, et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004;165(4):1289-1300.

[35] Breyhan H, Wirths O, Duan K, Marcello A, Rettig J, Bayer TA. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol. 2009;117(6):677-685.

[36] Wirths O, Breyhan H, Schäfer S, Roth C, Bayer TA. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol Aging. 2008;29(6):891-901.

[37] Christensen DZ, Kraus SL, Flohr A, Cotel M-C, Wirths O, Bayer TA. Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 2008;116(6):647-655.

[38] Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging. 2012;33(1):196.e29-196.e40.

[39] Sevalle J, Amoyel A, Robert P, Fournié-Zaluski MC, Roques B, Checler F. Aminopeptidase A contributes to the N-terminal truncation of amyloid β-peptide. J Neurochem. 2009;109(1):248-256.

[40] Cummins PM, O'Connor B. Pyroglutamyl peptidase: an overview of the three known enzymatic forms. Bioch Biophys Acta (BBA) - Protein Struct Mol Enzymol. 1998;1429(1):1-17.

[41] Lyons B, Friedrich M, Raftery M, Truscott R. Amyloid plaque in the human brain can decompose from Aβ(1-40/1-42) by spontaneous nonenzymatic processes. Anal Chem. 2016;88(5):2675-2684.

[42] Rudinskiy N, Fuerer C, Demurtas D, et al. Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. Alzheimer's Dement. 2016;12(9):996-1013.

[43] Walter S, Jumpertz T, Hüttenrauch M, et al. The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. Acta Neuropathol. 2019;137(2):239-257.

[44] Carare RO, Aldea R, Agarwal N, et al. Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of vascular professional interest area (PIA): cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease-opportunities for therapy. Alzheimer's Dement. 2020;12(1):e12053.

[45] Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. SYMPOSIUM: clearance of Aβ from the brain in Alzheimer's disease: perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 2008;18(2):253-266.

[46] Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Aβ peptide. Neuron. 2004;43(5):605-608.

[47] Saido T, Leissring MA. Proteolytic degradation of amyloid β-protein. Cold Spring Harbor Perspect Med. 2012;2(6):a006379.

[48] Hornung K, Zampar S, Engel N, et al. N-Terminal truncated Aβ4-42 is a substrate for neprilysin degradation in vitro and in vivo. J Alzheimer's Dis. 2019;67(3):849-858.

[49] Lee EB, Zhang B, Liu K, et al. BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo. J Cell Biol. 2005;168(2):291-302.

[50] Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biolog Chem. 2001;276(51):47863-47868.

[51] Yan P, Hu X, Song H, et al. Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ. J Biol Chem. 2006;281(34):24566-24574.

[52] Liao MC, Van Nostrand WE. Degradation of soluble and fibrillar amyloid β-protein by matrix metalloproteinase (MT1-MMP)in vitro. Biochemistry. 2010;49(6):1127-1136.

[53] Mueller-Steiner S, Zhou Y, Arai H, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron. 2006;51(6):703-714.

[54] Hamazaki H. Cathepsin D is involved in the clearance of Alzheimer's β-amyloid protein. FEBS Lett. 1996;396(2-3):139-142.

[55] Engelhardt B, Carare RO, Bechmann I, Flügel A, Laman JD, Weller RO. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol. 2016;132(3):317-338.

[56] Bakker ENTP, Bacskai BJ, Arbel-Ornath M, et al. Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell Mol Neurobiol. 2016;36(2):181-194.

[57] McIntee FL, Giannoni P, Blais S, et al. In vivo differential brain clearance and catabolism of monomeric and oligomeric Alzheimer's Aβ protein. Front Aging Neurosci. 2016;8:223.

[58] Vanderstichele H, De Meyer G, Andreasen N, et al. Amino-truncated β-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem. 2005;51(9):1650-1660.

[59] Domingo G, Benussi L, Saraceno C, et al. N-Terminally truncated and pyroglutamate-modified Aβ forms are measurable in human cerebrospinal fluid and are potential markers of disease progression in Alzheimer's disease. Front Neurosci. 2021;15:708119.

[60] Herzig MC, Winkler DT, Burgermeister P, et al. Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004;7(9):954-960.

[61] Thal DR, Ghebremedhin E, Rüb U, Yamaguchi H, Del Tredici K, Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002;61(3):282-293.

[62] Auriel E, Greenberg SM. The pathophysiology and clinical presentation of cerebral amyloid angiopathy. Curr Atherosclerosis Rep. 2012;14(4):343-350.

[63] Sagare AP, Bell RD, Zlokovic BV. Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. J Alzheimer's Dis. 2012;33(01):S87-S100.

[64] Jäkel L, Van Nostrand WE, Nicoll JAR, Werring DJ, Verbeek MM. Animal models of cerebral amyloid angiopathy. Clin Sci. 2017;131(19):2469-2488.

[65] Davis J, Xu F, Deane R, et al. Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid β-protein precursor. J Biol Chem. 2004;279(19):20296-20306.

[66] Foley KE, Weekman EM, Wilcock DM. Understanding the cellular responses to anti-Abeta antibodies to gain insights into mechanisms of ARIA. Alzheimer's Dement. 2024;20(S1):e085573.

[67] Banerjee G, Carare R, Cordonnier C, et al. The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. J Neurol Neurosurg Psychiatry. 2017;88(11):982-994.

[68] Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56(4):537-539.

[69] Sin M-K, Dage JL, Nho K, et al. Plasma biomarkers for cerebral amyloid angiopathy and implications for amyloid-related imaging abnormalities: a comprehensive review. J Clin Med. 2025;14(4):1070.

[70] Zampar S, Wirths O. Immunotherapy targeting Amyloid-β peptides in Alzheimer's disease. In: Huang X, ed. Alzheimer's Disease: Drug Discovery. Exon Publications; 2020.

[71] Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175-193.

[72] Mantile F, Prisco A. Vaccination against β-Amyloid as a strategy for the prevention of Alzheimer's disease. Biology. 2020;9(12):425.

[73] Fox NC, Black RS, Gilman S, et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64(9):1563-1572.

[74] Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature. 2002;415(6871):462.

[75] Wirths O, Walter S, Kraus I, et al. N-truncated Aβ(4-x) peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models. Alzheimer's Res Ther. 2017;9(1):80.

[76] Cabrera E, Mathews P, Mezhericher E, et al. Aβ truncated species: implications for brain clearance mechanisms and amyloid plaque deposition. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2018;1864(1):208-225.

[77] Valle ML, Getaneh B, Loveland J, et al. Protocol for culture, purification, and target validation of a hybridoma-generated monoclonal antibody targeting Aβ truncated species. STAR Protocols. 2025;6(2):103864.

[78] Zampar S, Klafki HW, Sritharen K, et al. N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease. Neuropathol Appl Neurobiol. 2020;46(7):673-685.

[79] Wirths O, Lehnen C, Fricke M, et al. Amino-terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer's disease brains. Neuropathol Appl Neurobiol. 2024;50(3):e12991.

[80] Miles LA, Crespi GAN, Doughty L, Parker MW. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep. 2013;3:1302.

[81] Gkanatsiou E, Portelius E, Toomey CE, et al. A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. Neurosci Lett. 2019;701: 125-131.

[82] McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nature Med. 2002;8(11):1263-1269.

[83] Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-177.

[84] Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8(1):248.

[85] Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 2003;61(1):46-54.

[86] Antonios G, Borgers H, Richard BC, et al. Alzheimer therapy with an antibody against N-terminal abeta 4-X and pyroglutamate Abeta 3-X. Sci Rep. 2015;5(1):17338.

[87] Bader AS, Gnädig MU, Fricke M, et al. Brain region-specific differences in amyloid-β plaque composition in 5XFAD mice. Life. 2023;13(4):1053.

[88] Talucci I, Leske T, Klafki H-W, et al. Aggregation-dependent epitope sequence and modification fingerprints of anti-Aβ antibodies. eLife. 2026;14:RP106156.

[89] Savastano A, Klafki H, Haußmann U, et al. N-Truncated Aβ2-X starting with position two in sporadic Alzheimer's disease cases and two Alzheimer mouse models. J Alzheimer's Dis. 2015;49(1):101-110.

[90] Wiltfang J, Esselmann H, Cupers P, et al. Elevation of β-Amyloid peptide 2–42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem. 2001;276(46):42645-42657.

[91] Armbrust F, Bickenbach K, Altmeppen H, et al. A novel mouse model for N-terminal truncated Aβ2-x generation through meprin β overexpression in astrocytes. Cell Mol Life Sci. 2024;81(1):139.

[92] Saido TC, Iwatsubo T, Mann DMA, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron. 1995;14(2):457-466.

[93] Schlenzig D, Cynis H, Hartlage-Rübsamen M, et al. Dipeptidyl-Ppeptidase activity of meprin β links n-truncation of Aβ with glutaminyl cyclase-catalyzed pGlu-Aβ formation. J Alzheimer's Dis. 2018;66(1):359-375.

[94] He W, Barrow CJ. The Aβ 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater β-sheet forming and aggregation propensities in vitro than full-length Aβ. Biochemistry. 1999;38(33):10871-10877.

[95] Crehan H, Liu B, Kleinschmidt M, et al. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. Alzheimer's Res Ther. 2020;12(1):12.

[96] Takeda K, Araki W, Akiyama H, Tabira T. Amino-truncated amyloid β-peptide (Aβ5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. FASEB J. 2004;18(14):1755-1757.

[97] Takeda K, Araki W, Akiyama H, Tabira T. Amino-truncated amyloid β-peptide (Aβ5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. FASEB J. 2004;18(14):1755-1757.

[98] Guzmán EA, Bouter Y, Richard BC, et al. Abundance of Aβ5-xlike immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease. Mol Neurodegener. 2014;9:13.

[99] Yadollahikhales G, Rojas JC. Anti-amyloid immunotherapies for Alzheimer's disease: a 2023 clinical update. Neurotherapeutics. 2023;20(4):914-931.

[100] Salloway S, Farlow M, McDade E, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Med. 2021;27(7):1187-1196.

[101] Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322-333.

[102] van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.

[103] Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527.

[104] Johannesson M, Söderberg L, Zachrisson O, et al. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Mol Cell Neurosci. 2024;130:103949.

[105] Albertini G, Zielonka M, Cuypers M-L, et al. The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia. Nature Neurosci. 2025;29:100-110.

[106] Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691-1704.

[107] Bouter Y, Liekefeld H, Pichlo S, et al. Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer's disease and Down syndrome. Acta Neuropathol. 2022;143(5):601-603.

[108] Chantran Y, Capron J, Alamowitch S, Aucouturier P. Anti-Aβ antibodies and cerebral amyloid angiopathy complications. Front Immunol. 2019;10:1534.

[109] Cummings JL, Cohen S, van Dyck CH, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889-e1897.

RIGHTS & PERMISSIONS

2026 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.